Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05042128
Title The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND)
Recruitment Recruiting
Phase Phase II
Variant Requirements No
Sponsors Australasian Gastro-Intestinal Trials Group

pancreatic carcinoma

pancreatic ductal adenocarcinoma


Gemcitabine + Nab-paclitaxel

CEND-1 + Gemcitabine + Nab-paclitaxel

Age Groups: senior | adult
Covered Countries

No variant requirements are available.